Table 1.

Summary of representative clinical studies evaluating FAPI PET/CT

Authors	Year	Radiopharmaceutical	Population	Number of patients	Method	Ref
Lindner et al	2018	68 Ga-FAPI-04	Breast cancer	2	Prospective	[35]
Giesel et al	2019	68 Ga-FAPI-02/04; 18F-FDG	Mixed population of different cancers	50	Prospective	[27]
Hathi et al	2019	68 Ga-FAPI-04	Mixed population of different cancers	54	Prospective	[33]
Röhrich et al	2019	68 Ga-FAPI-02/04	Glioma	18	Prospective	[46]
Chen et al	2020	68 Ga-FAPI-04; 1SF-FDG	Mixed population of different cancers	75	Prospective	[154]
Chen et al	2020	68 Ga-FAPI-04; 1SF-FDG	Mixed patients with inconclusive 18F-FDG findings	68	Prospective	[155]
Syed et al	2020	68 Ga-FAPI-04	Head and neck cancers	14	Prospective	[134]
Giesel et al	2020	18F-FAPI-74;68 Ga-FAPI-74	Lung cancers	10	Prospective	[42]
Shi et al	2020	68 Ga-FAPI-04	Hepatobiliary cancers	25	Prospective	[66]
Koerber et al	2020	68 Ga-FAPI-04/46	Colorectal and anal cancers	16	Prospective	[60]
Luo et al	2020	68 Ga-FAPI-04; 1SF-FDG	IgG4-RD	26	Prospective	[97]
Lindner et al	2020	99mTc-FAPI-34	Ovarian and pancreatic cancers	2	Prospective	[144]
Zhang et al	2021	68 Ga-FAPI-04	Mixed patients with different diseases	103	Retrospective	[72]
Zhao et al	2021	68 Ga-DOTA-2P(FAPI)2	Healthy volunteers and different cancer patients	6	Prospective	[141]
Mona et al	2021	68 Ga-FAPI-46	Mixed patients with different diseases	141	Prospective	[156]
Gundogan et al	2021	68 Ga-FAPI-04	Gastric adenocarcinoma	21	Prospective	[157]
Pang et al	2021	68 Ga-FAPI-04	Pancreatic cancers	36	Retrospective	[71]
Ballal et al	2021	68 Ga-DOTA.SA.FAPI	Radioiodine-refractory differentiated thyroid cancer	15	Prospective	[143]
Lan et al	2021	68 Ga-FAPI-04	Mixed patients with different diseases	123	Prospective	[158]
Kuten et al	2021	68 Ga-FAPI-04	Gastric adenocarcinoma	13	Prospective	[57]
Qin et al	2021	68 Ga-FAPI-04	Nasopharyngeal carcinoma	15	Prospective	[39]
Qin et al	2021	68 Ga-FAPI-04	Gastric carcinomas	20	Prospective	[59]